Initially used to treat rheumatoid arthritis, nonselective therapeutic leukocytapheresis was
applied to the treatment of inflammatory bowel disease (IBD) as early as the 1980s. Since …

Leukocytapheresis, device used to remove leukocytes from peripheral circulation, has been
approved for the treatment of active ulcerative colitis (UC) by the Ministry of Health and …

The etiology of inflammatory bowel disease (IBD) is not completely understood, thus current
therapies have been empirical and directed at treating symptoms rather than addressing the …

Inflammatory bowel disease is characterized by clinical remission and relapse caused by
severe intestinal inflammation. Drug therapy for inflammatory bowel disease is associated …

In patients with inflammatory bowel disease (IBD), centrifugation has been attempted to
remove leukocyte components from whole blood; however, the use of selective filters has …

Therapeutic apheresis, a novel approach for immunodisorders, has been used in the last
decade for the treatment of ulcerative colitis with promising result, and represents an …

Intense infiltration of the intestinal mucosa by activated leukocytes is a hallmark of
inflammatory bowel disease (IBD). Therefore, removal of circulating leukocytes may be an …

We have studied the effects of granulocyte apheresis in 18 patients with ulcerative colitis
and 6 with Crohn's disease who had failed to respond to conventional therapy. Patients …

Cytapheresis therapy has recently been investigated as a treatment for several diseases,
especially autoimmune related diseases such as rheumatoid arthritis, systemic lupus …

Ulcerative colitis and Crohn's disease are the two most prevalent inflammatory bowel
diseases. In both cases, the medically refractory and steroid-dependent type presents a …